The study analyses the operational-scientific peculiarities of the development process of innovative therapies (Atmps), showing how these make the clinical-economic evaluation complex and the traditional decision-making and intervention models of «Finance» ineffective. The study highlights how the intervention of Finance is limited and takes place, only, through debt/equity investments in BioTechs (Smes and startups). There is a need to coordinate the intervention of public, non-profit and private finance to reduce dispersion, be more consistent with the objectives of the various stakeholders and contribute to making investment in innovative therapies more sustainable, also through new models for evaluating the value created.
